Chronic Venous Insufficiency (CVI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Chronic Venous Insufficiency (CVI) is where the venous wall and valves in the leg veins lose effectiveness, making it challenging for blood to flow back to the heart from the legs. This results in the accumulation of blood in these veins, a condition known as stasis. The causes of CVI can be categorized as either primary or secondary, with primary CVI being symptomatic without any specific triggering event, often due to congenital defects or changes in the venous wall's biochemistry. Secondary CVI, on the other hand, occurs in response to deep venous thrombosis (DVT), which initiates an inflammatory reaction, causing damage to the vein wall. Regardless of the underlying cause, CVI leads to elevated venous pressure. Several risk factors contribute to the development of CVI, including advanced age, a history of deep vein thrombosis, a sedentary lifestyle, oral contraceptives, leg injuries, and hypertension. The treatment approach for patients with chronic venous insufficiency depends on the severity and nature of the condition. The primary objectives of treatment are to alleviate discomfort and reduce swelling, stabilize the appearance of the skin, eliminate painful varicose veins, and promote the healing of ulcers. Usually, initial treatment involves conservative measures such as elevating the legs, engaging in exercises to improve calf muscle function, managing weight, and using compression therapy. It's important to note that compression therapy is a long-term solution and is effective only when patients adhere to it.
·
Chronic Venous Insufficiency predominantly
affects the lower limbs, with a prevalence ranging from 25% to 40% in women and
10% to 20% in men. According to Thelansis disease modeling data, results of
literature reviews, surveys, and registry analyses estimate that 2.3-6.2% of
all residents of the USA have some changes associated with CVI
Thelansis’s
“Chronic Venous Insufficiency (CVI) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2023 To 2033" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Chronic
Venous Insufficiency (CVI) treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Chronic Venous Insufficiency
(CVI) across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Chronic
Venous Insufficiency (CVI) Market Forecast Patient Based Forecast Model (MS.
Excel Based Automated Dashboard), which Data Inputs with sourcing, Market
Event, and Product Event, Country specific Forecast Model, Market uptake and
patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and
pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Chronic
Venous Insufficiency (CVI), Chronic Venous Insufficiency (CVI) market outlook, Chronic Venous Insufficiency (CVI) competitive landscape, Chronic Venous Insufficiency
(CVI) market forecast, Thelansis, Primary market
research, KOL insights, Competitive Intelligence (CI)
Comments
Post a Comment